Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?
Crossref DOI link: https://doi.org/10.1186/s13014-016-0657-z
Published Online: 2016-07-07
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jensen, A. D.
Poulakis, M.
Vanoni, V.
Uhl, M.
Chaudhri, N.
Federspil, P. A.
Freier, K.
Krauss, J.
Debus, J.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG)